Eikon Therapeutics Inc (EIKN)

NASDAQHealth CareBiotechnologySnapshot 2026-11-05

$5.84-8.61%

Close 2026-11-05 · 1-day change

QuarterlyIQ Insights · EIKN

News & Events

Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.

Type

Direction

6 matches

2026-10-26Item 8.01
EIKN — litigation filed
Other Events. On October 26, 2026, the Company presented updated data from its TeLuRide-005 trial of EIK1001 at the 2026 ESMO Congress, detailed below. EIK1001 Clinical Update: Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with advanced non-small cell lung cancer (NSCLC) demonstrates potentially durable effect of EIK1001 in combination with standard of car…
Legal / regulatorylitigation filednegative
2026-08-13Item 2.02
EIKN — earnings miss
Results of Operations and Financial Condition. On August 13, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purpo…
Earnings preannouncementearnings missnegative
2026-08-03Item 5.02
EIKN — officer change
Director — Leon Chen, Ph.D. and Joshua Wolfe: Dr. Leon Chen and Mr. Joshua Wolfe resigned from the Board of Directors without a stated successor.
Executive changedeparturenegative
2026-06-10Item 5.02
EIKN — director transition
Class I director — Ma. Fatima D. Francisco: Ms. Francisco was appointed to the Board of Directors as a Class I director.
Executive changeinternal promotionneutral
2026-05-11Item 2.02
EIKN — earnings miss
Results of Operations and Financial Condition. On May 11, 2026, Eikon Therapeutics, Inc. (the "Company") issued a press release announcing clinical and corporate updates and its financial results for the quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Earnings preannouncementearnings missnegative
2026-03-30Item 2.02
EIKN — earnings miss
Results of Operations and Financial Condition. On March 30, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purp…
Earnings preannouncementearnings missnegative

Coming next

General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.